CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04Corinne Summers, Rebecca Gardner, Stephanie Rhea et al.|Blood|2021Cited by 9
Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell TherapyFrancesco Ceppi, Michael C. Jensen, Colleen Annesley et al.|Blood|2018Cited by 6